Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASTC Astrotech	$5.68 +1.3%	$5.79	$5.34 ▼ $12.29	$9.59M	0.25	15,012 shs	2,459 shs
AXDX Accelerate Diagnostics		$0.65	$0.03 ▼ $2.09	$857K	0.22	537,509 shs	53.64 million shs
EYPT Eyepoint Pharmaceuticals	$11.17 +1.9%	$7.87	$3.91 ▼ $13.99	$757.25M	1.67	820,470 shs	297,645 shs
FLDM Fluidigm		$3.66	$2.67 ▼ $7.51	$283.76M	1.14	968,838 shs	60,126 shs
HBIO Harvard Bioscience	$0.45 -1.2%	$0.43	$0.28 ▼ $3.60	$19.98M	1.52	3.15 million shs	318,712 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASTC Astrotech	-0.36%	0.00%	-2.61%	-9.24%	-34.04%
AXDX Accelerate Diagnostics	0.00%	0.00%	0.00%	-93.02%	-96.48%
EYPT Eyepoint Pharmaceuticals	+10.15%	+13.46%	+22.73%	+128.33%	+24.97%
FLDM Fluidigm	0.00%	0.00%	0.00%	0.00%	0.00%
HBIO Harvard Bioscience	-0.20%	-2.58%	-18.07%	+18.59%	-83.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASTC Astrotech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AXDX Accelerate Diagnostics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EYPT Eyepoint Pharmaceuticals	2.8094 of 5 stars	3.5	3.0	0.0	0.0	3.7	1.7	0.0
FLDM Fluidigm	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HBIO Harvard Bioscience	4.1413 of 5 stars	3.3	4.0	0.0	4.5	1.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASTC Astrotech	0.00	N/A	N/A	N/A
AXDX Accelerate Diagnostics	4.00	Strong Buy	N/A	N/A
EYPT Eyepoint Pharmaceuticals	3.00	Buy	$25.67	131.75% Upside
FLDM Fluidigm	0.00	N/A	N/A	N/A
HBIO Harvard Bioscience	2.50	Moderate Buy	$3.00	563.72% Upside

Current Analyst Ratings Breakdown

Latest AXDX, EYPT, FLDM, HBIO, and ASTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	EYPT Eyepoint Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$28.00
5/29/2025	EYPT Eyepoint Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
5/16/2025	EYPT Eyepoint Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $26.00
5/13/2025	HBIO Harvard Bioscience	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Speculative Buy ➝ Speculative Buy	$4.50 ➝ $3.00
5/8/2025	EYPT Eyepoint Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$33.00 ➝ $27.00

(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASTC Astrotech	$1.66M	5.78	N/A	N/A	$20.45 per share	0.28
AXDX Accelerate Diagnostics	$11.70M	0.00	N/A	N/A	($1.37) per share	0.00
EYPT Eyepoint Pharmaceuticals	$43.27M	17.61	N/A	N/A	$4.93 per share	2.25
FLDM Fluidigm	$130.58M	0.00	N/A	N/A	$1.24 per share	0.00
HBIO Harvard Bioscience	$94.14M	0.21	$0.10 per share	4.54	$1.45 per share	0.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASTC Astrotech	-$11.67M	-$8.42	N/A	∞	N/A	-1,536.99%	-46.37%	-42.51%	9/17/2025 (Estimated)
AXDX Accelerate Diagnostics	-$61.62M	-$2.34	N/A	N/A	N/A	-471.83%	N/A	-191.66%	N/A
EYPT Eyepoint Pharmaceuticals	-$130.87M	-$2.41	N/A	N/A	N/A	-261.91%	-54.27%	-41.75%	8/6/2025 (Estimated)
FLDM Fluidigm	-$59.24M	-$0.78	N/A	N/A	N/A	-45.36%	-40.15%	-14.86%	N/A
HBIO Harvard Bioscience	-$12.40M	-$1.32	N/A	∞	N/A	-63.51%	-4.96%	-2.24%	8/14/2025 (Estimated)

Latest AXDX, EYPT, FLDM, HBIO, and ASTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	EYPT Eyepoint Pharmaceuticals	-$0.67	N/A	N/A	N/A	$6.82 million	N/A
5/13/2025	Q3 2025	ASTC Astrotech	N/A	-$2.18	N/A	-$2.18	N/A	N/A
5/7/2025	Q1 2025	EYPT Eyepoint Pharmaceuticals	-$0.65	-$0.65	N/A	-$0.65	$8.84 million	$24.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASTC Astrotech	N/A	N/A	N/A	N/A	N/A
AXDX Accelerate Diagnostics	N/A	N/A	N/A	N/A	N/A
EYPT Eyepoint Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FLDM Fluidigm	N/A	N/A	N/A	N/A	N/A
HBIO Harvard Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASTC Astrotech	N/A	9.86	8.76
AXDX Accelerate Diagnostics	N/A	1.50	1.34
EYPT Eyepoint Pharmaceuticals	N/A	7.85	7.79
FLDM Fluidigm	0.68	1.45	1.03
HBIO Harvard Bioscience	N/A	0.81	0.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASTC Astrotech	24.35%
AXDX Accelerate Diagnostics	17.14%
EYPT Eyepoint Pharmaceuticals	99.41%
FLDM Fluidigm	76.59%
HBIO Harvard Bioscience	80.87%

Insider Ownership

Company	Insider Ownership
ASTC Astrotech	14.90%
AXDX Accelerate Diagnostics	43.60%
EYPT Eyepoint Pharmaceuticals	4.46%
FLDM Fluidigm	2.90%
HBIO Harvard Bioscience	9.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASTC Astrotech	10	1.69 million	1.44 million	Not Optionable
AXDX Accelerate Diagnostics	220	25.21 million	14.13 million	Optionable
EYPT Eyepoint Pharmaceuticals	120	68.81 million	65.74 million	Optionable
FLDM Fluidigm	615	76.49 million	74.27 million	Optionable
HBIO Harvard Bioscience	490	44.21 million	40.01 million	Optionable

AXDX, EYPT, FLDM, HBIO, and ASTC Headlines

Recent News About These Companies

Trump administration formally subpoenas Harvard University over foreign student information

1 hour ago | msn.com

Harvard slapped with subpoenas as Trump admin probes foreign student exchange program

July 10 at 9:54 AM | msn.com

Trump admin comes for Harvard’s accreditation

July 10 at 9:54 AM | msn.com

Harvard College, Faculty of Arts and Sciences Replace Diversity Offices Amid DEI Purge

July 10 at 9:54 AM | thecrimson.comT

US escalates fight over Harvard’s international student data

July 10 at 9:54 AM | thepienews.comT

Websites serving Harvard undergrad women, minority and LGBTQ students taken down, Crimson reports

July 10 at 9:54 AM | cnn.com

Trump Administration Attacks Harvard’s Accreditation

July 9 at 11:22 PM | msn.com

Trump Administration Warns Harvard It Risks Losing Accreditation Status

July 9 at 11:22 PM | msn.com

Trump Admin Gets One Step Closer To Making Harvard’s Worst Nightmare Come True

July 9 at 11:22 PM | ijr.comI

Trump Administration Targets Harvard Over Antisemitism, International Students

July 9 at 11:22 PM | econotimes.com

Trump administration threatens Harvard's accreditation, seeks records on foreign students

July 9 at 11:22 PM | msn.com

Trump administration says it will subpoena Harvard for info on foreign students

July 9 at 11:22 PM | msn.com

Trump vs Harvard: Govt threatens university's accreditation over foreign student data —who will blink first?

July 9 at 11:22 PM | msn.com

Harvard vs. Trump latest: Subpoenas issued, accreditor warned

July 9 at 11:22 PM | msn.com

Trump administration subpoenas Harvard for records on international students

July 9 at 11:22 PM | baltimoresun.comB

Harvard, Other Ivies With Healthy Endowments Face Hefty New Taxes With Passage of Trump’s Signature Spending Bill

July 8 at 9:05 PM | nysun.comN

Trinity College appoints Harvard dean, former UConn official as new VP and CFO

July 8 at 9:05 PM | newstimes.comN

If your partner uses any of these 7 phrases every day, it means they ‘truly trust' you: Harvard-trained psychologist

July 8 at 9:05 PM | nbclosangeles.comN

Harvard, other Ivies hit with endowment tax hike in Trump spending bill

July 8 at 9:05 PM | msn.com

Research institute, affiliated with Harvard and MIT, lays off 75

July 8 at 9:05 PM | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXDX, EYPT, FLDM, HBIO, and ASTC Company Descriptions

Astrotech NASDAQ:ASTC

$5.68 +0.08 (+1.34%)

As of 03:43 PM Eastern

Astrotech Corporation operates as a mass spectrometry company worldwide. It owns and licenses the intellectual property related to the Astrotech Mass Spectrometer Technology, a platform mass spectrometry technology. The company also develops TRACER 1000, a mass spectrometer-based explosive trace detector to replace the explosives trace detectors used at airports, cargo and other secured facilities, and borders. In addition, it develops AgLAB-1000, a mass spectrometer for use in the hemp and cannabis market. Further, the company develops BreathTest-1000, a breath analysis tool to screen for volatile organic compound metabolites found in a person's breath. The company was formerly known as SPACEHAB, Inc. and changed its name to Astrotech Corporation in 2009. The company was incorporated in 1984 and is based in Austin, Texas.

Accelerate Diagnostics NASDAQ:AXDX

$0.04 +0.04 (+∞)

As of 05/14/2025

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Eyepoint Pharmaceuticals NASDAQ:EYPT

$11.16 +0.21 (+1.87%)

As of 03:45 PM Eastern

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Fluidigm NASDAQ:FLDM

Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Harvard Bioscience NASDAQ:HBIO

$0.45 -0.01 (-1.18%)

As of 03:42 PM Eastern

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time